Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV-2 NSP14
Non-structural protein 14 (NSP14) is a key two-domain protein responsible for maintaining coronavirus replication fidelity, and in its absence reproduction is severely impacted. With the goal of identifying new inhibitors of SARS-CoV-2 NSP14, we selected a previously reported scaffold as an appropriate starting point. Medicinal chemistry exploration provided a series of trisubstituted pyrazolines as inhibitors of NSP14 methyltransferase (MTase) activity, with improved synthetic tractability and in a promising molecular property space. This led to compound <b>35</b> as a potent inhibitor of NSP14 MTase with a favorable <i>in vitro</i> ADMET profile, and antiviral activity against SARS-CoV-2 replication. We propose that <b>35</b> is a useful chemical probe which is well-positioned to further interrogate <i>in vitro</i> biology and for further optimization toward the treatment of human coronaviruses.
Authors
- Jonathan M. Large
- Richard Foster (ORCID: https://orcid.org/0000-0002-2361-3884)
- Elizabeth Smyth
- Arvind H. Patel (ORCID: https://orcid.org/0000-0003-4600-2047)
- Nicole Upfold (ORCID: https://orcid.org/0000-0001-8556-0370)
- Kristian Birchall (ORCID: https://orcid.org/0000-0001-9992-2555)
- João Pedro Pisco (ORCID: https://orcid.org/0000-0001-6763-7354)
Institutions
- LifeArc (GB)
- University of Leeds (GB)
- MRC University of Glasgow Centre for Virus Research (GB)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00155
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- LifeArc
- Royal Commission for the Exhibition of 1851
- Medical Research Council